JP2008510468A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008510468A5 JP2008510468A5 JP2007528061A JP2007528061A JP2008510468A5 JP 2008510468 A5 JP2008510468 A5 JP 2008510468A5 JP 2007528061 A JP2007528061 A JP 2007528061A JP 2007528061 A JP2007528061 A JP 2007528061A JP 2008510468 A5 JP2008510468 A5 JP 2008510468A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- polypeptide
- acid sequence
- arginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims 58
- 235000001014 amino acid Nutrition 0.000 claims 49
- 150000001413 amino acids Chemical class 0.000 claims 46
- 125000003275 alpha amino acid group Chemical group 0.000 claims 33
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 17
- 239000004475 Arginine Substances 0.000 claims 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 235000013922 glutamic acid Nutrition 0.000 claims 7
- 239000004220 glutamic acid Substances 0.000 claims 7
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 239000000539 dimer Substances 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 239000013604 expression vector Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108091008551 RET receptors Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60282504P | 2004-08-19 | 2004-08-19 | |
| US60/602,825 | 2004-08-19 | ||
| US69406705P | 2005-06-24 | 2005-06-24 | |
| US60/694,067 | 2005-06-24 | ||
| PCT/US2005/029637 WO2006023781A2 (en) | 2004-08-19 | 2005-08-18 | Neublastin variants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011108760A Division JP2011155987A (ja) | 2004-08-19 | 2011-05-13 | ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008510468A JP2008510468A (ja) | 2008-04-10 |
| JP2008510468A5 true JP2008510468A5 (enExample) | 2008-06-26 |
| JP4852545B2 JP4852545B2 (ja) | 2012-01-11 |
Family
ID=35968235
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007528061A Expired - Fee Related JP4852545B2 (ja) | 2004-08-19 | 2005-08-18 | ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体 |
| JP2011108760A Withdrawn JP2011155987A (ja) | 2004-08-19 | 2011-05-13 | ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011108760A Withdrawn JP2011155987A (ja) | 2004-08-19 | 2011-05-13 | ニューブラスチン（Ｎｅｕｂｌａｓｔｉｎ）変異体 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8263553B2 (enExample) |
| EP (3) | EP1786454B1 (enExample) |
| JP (2) | JP4852545B2 (enExample) |
| KR (2) | KR101215697B1 (enExample) |
| CN (1) | CN102924585A (enExample) |
| AT (1) | ATE474586T1 (enExample) |
| AU (1) | AU2005277226B2 (enExample) |
| BR (1) | BRPI0514534A (enExample) |
| CA (1) | CA2577755C (enExample) |
| CY (1) | CY1111136T1 (enExample) |
| DE (1) | DE602005022457D1 (enExample) |
| DK (1) | DK1786454T3 (enExample) |
| EA (1) | EA013565B1 (enExample) |
| GE (1) | GEP20115196B (enExample) |
| HR (1) | HRP20100474T1 (enExample) |
| IL (2) | IL181311A (enExample) |
| MX (1) | MX2007002029A (enExample) |
| NO (1) | NO20071449L (enExample) |
| NZ (1) | NZ553431A (enExample) |
| PL (1) | PL1786454T3 (enExample) |
| PT (1) | PT1786454E (enExample) |
| RS (1) | RS51453B (enExample) |
| SI (1) | SI1786454T1 (enExample) |
| UA (1) | UA92590C2 (enExample) |
| WO (1) | WO2006023781A2 (enExample) |
| ZA (1) | ZA200701395B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| US7276580B2 (en) * | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| JP4571776B2 (ja) * | 2002-11-05 | 2010-10-27 | Ｊｘ日鉱日石エネルギー株式会社 | 潤滑油組成物 |
| EP1897552B1 (en) | 2003-04-18 | 2009-06-17 | Biogen Idec MA Inc. | Polymer-conjugated glycosylated neublastin |
| DK1786454T3 (da) | 2004-08-19 | 2010-09-06 | Biogen Idec Inc | Neublastinvarianter |
| CN101043899B (zh) | 2004-08-19 | 2011-03-30 | 比奥根艾迪克Ma公司 | 重折叠转化型生长因子beta家族蛋白 |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| US20100056440A1 (en) * | 2006-03-01 | 2010-03-04 | Biogen Idec Ma Inc. | Compositions and methods for administering gdnf ligand family proteins |
| TWI445544B (zh) | 2007-05-01 | 2014-07-21 | Biogen Idec Inc | 增進血管形成之組合物及方法 |
| US20110135648A1 (en) * | 2007-08-08 | 2011-06-09 | Biogen Idec Ma Inc. | Anti-neublastin antibodies and uses thereof |
| WO2015042580A1 (en) | 2013-09-23 | 2015-03-26 | Biogen Idec Ma Inc. | Compositions and methods for treatment of neuropathic pain |
| WO2016022800A1 (en) | 2014-08-07 | 2016-02-11 | Biogen Ma Inc. | Characterization of cystine knot superfamily proteins |
| CA3124660A1 (en) * | 2018-12-21 | 2020-06-25 | Gloriana Therapeutics Sarl | Mammalian cell culture-produced neublastin antibodies |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
| DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
| US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
| US5618531A (en) | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| ES2141108T3 (es) | 1991-07-02 | 2000-03-16 | Inhale Inc | Metodo y dispositivo para proporcionar medicamentos en aerosol. |
| WO1993006116A1 (en) | 1991-09-20 | 1993-04-01 | Syntex-Synergen Neuroscience Joint Venture | Glial derived neurotrophic factor |
| US5939524A (en) | 1991-12-09 | 1999-08-17 | The Scripps Research Institute | Platelet GPIII P1A1 and P1A2 epitopes, their preparation and use |
| US5414135A (en) | 1991-12-30 | 1995-05-09 | Sterling Winthrop Inc. | Vinyl sulfone coupling of polyoxyalkylenes to proteins |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| DK0679088T3 (da) | 1992-09-29 | 2002-10-28 | Inhale Therapeutic Syst | Pulmonal levering af aktive fragmenter af parathyreoideaea hormon |
| US5349056A (en) | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
| CA2092271C (en) | 1993-03-09 | 2009-10-13 | Eddie Reed | Use of g-csf for treating taxol side-effects |
| ES2178654T3 (es) | 1993-08-12 | 2003-01-01 | Neurotech Sa | Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas. |
| DE4339605A1 (de) | 1993-11-20 | 1995-05-24 | Beiersdorf Ag | Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden |
| US5834029A (en) | 1994-07-20 | 1998-11-10 | Cytotherapeutics, Inc. | Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US5770577A (en) | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
| US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
| US5733729A (en) | 1995-09-14 | 1998-03-31 | Affymetrix, Inc. | Computer-aided probability base calling for arrays of nucleic acid probes on chips |
| US5641749A (en) | 1995-11-29 | 1997-06-24 | Amgen Inc. | Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product |
| US6063757A (en) | 1995-11-29 | 2000-05-16 | Urso; Richard G. | Wound treatment method with nerve growth factor |
| EP0943690B1 (en) | 1995-12-21 | 2006-11-29 | Ajinomoto Co., Inc. | Method for refolding human activin a |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
| US5754524A (en) | 1996-08-30 | 1998-05-19 | Wark; Barry J. | Computerized method and system for analysis of an electrophoresis gel test |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| JP2001501093A (ja) | 1996-09-26 | 2001-01-30 | メディカル リサーチ カウンシル | シャペロン断片 |
| KR100195886B1 (ko) | 1996-11-01 | 1999-06-15 | 김상조 | 당뇨병 치료용 의약조성물 |
| US6653098B1 (en) | 1998-02-23 | 2003-11-25 | G. D. Searle & Co. | Method of producing mouse and human endostatin |
| US20020055467A1 (en) | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
| US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
| PL209952B1 (pl) | 1998-07-14 | 2011-11-30 | Janssen Pharmaceutica Nv | Wyizolowana cząsteczka kwasu nukleinowego, wyizolowany ludzki neurotroficzny czynnik wzrostu, plazmid, wektor ekspresyjny, komórka gospodarza, zastosowania cząsteczki kwasu nukleinowego, zastosowania neurotroficznego czynnika wzrostu, kompozycje faramaceutyczne, przeciwciało oraz sposób wykrywania neurotroficznego czynnika wzrostu |
| US7067473B1 (en) | 1998-07-14 | 2006-06-27 | Janssen Pharmaceutica N.V. | Neurotrophic growth factor |
| JP2003524381A (ja) | 1998-09-22 | 2003-08-19 | ユニヴァーシティ オブ メリーランド，ボルチモア | システインノット成長因子ミュータント |
| US20020002269A1 (en) | 1998-09-29 | 2002-01-03 | Jeffrey D. Milbrandt | Artemin, a neurotrophic factor |
| US6361771B1 (en) | 1999-04-06 | 2002-03-26 | Neurotech S.A. | ARPE-19 as a platform cell line for encapsulated cell-based delivery |
| MXPA01010692A (es) | 1999-04-22 | 2004-09-06 | Univ Zuerich | Matrices de proteina modificadas para ingenieria de tejidos o liberacion controlada. |
| DE60002496T2 (de) | 1999-10-29 | 2004-03-25 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Verwendung von gdnf für behandlung von hornhautdefekten |
| CA2327208A1 (en) | 2000-11-30 | 2002-05-30 | The Government Of The United States Of America | Methods of increasing distribution of therapeutic agents |
| AU2002232785B2 (en) | 2000-12-22 | 2006-05-18 | Genentech, Inc. | Use of artemin, a member of the GDNF ligand family for preparing a neuroprotective medicament |
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| JP4259868B2 (ja) * | 2001-02-01 | 2009-04-30 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | ニューブラスチンのポリマー結合体および同様の使用方法。 |
| US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| ES2374971T3 (es) * | 2001-03-28 | 2012-02-23 | Biogen Idec Ma Inc. | Uso de polipéptidos de neublastina para el tratamiento del dolor neuropático. |
| US20040077543A1 (en) | 2001-03-28 | 2004-04-22 | Sah Dinah W. Y. | Treatment using neublastin polypeptides |
| ES2382899T3 (es) | 2001-04-24 | 2012-06-14 | Purdue Research Foundation | Método y composiciones para tratar lesiones en tejido nervioso de mamífero |
| US20030125521A1 (en) | 2001-06-20 | 2003-07-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
| US7129085B2 (en) | 2001-10-11 | 2006-10-31 | Bristol-Myers Squibb Company | Polynucleotides encoding a human leucine-rich repeat domain containing protein, HLLRCR-1 |
| GB0205022D0 (en) | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
| JP4310608B2 (ja) | 2002-04-25 | 2009-08-12 | 東洋紡績株式会社 | Ｈｓｐ７０ファミリータンパク質基質結合ドメインフラグメントの利用方法 |
| EP1897552B1 (en) | 2003-04-18 | 2009-06-17 | Biogen Idec MA Inc. | Polymer-conjugated glycosylated neublastin |
| AU2004245175C1 (en) | 2003-06-10 | 2010-03-18 | Biogen Ma Inc. | Improved secretion of neublastin |
| US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
| US20050180957A1 (en) | 2004-01-16 | 2005-08-18 | Scharp David W. | Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells |
| CN101031645B (zh) | 2004-06-23 | 2011-06-08 | 组织基因股份有限公司 | 神经再生 |
| US7598356B2 (en) | 2004-07-08 | 2009-10-06 | Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center | Method for purifying a protein of the cystine-knot superfamily |
| CN101043899B (zh) | 2004-08-19 | 2011-03-30 | 比奥根艾迪克Ma公司 | 重折叠转化型生长因子beta家族蛋白 |
| DK1786454T3 (da) | 2004-08-19 | 2010-09-06 | Biogen Idec Inc | Neublastinvarianter |
| WO2007042040A2 (en) | 2005-10-11 | 2007-04-19 | Ns Gene A/S | TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| US20100056440A1 (en) | 2006-03-01 | 2010-03-04 | Biogen Idec Ma Inc. | Compositions and methods for administering gdnf ligand family proteins |
| SI2019683T2 (sl) | 2006-04-25 | 2022-10-28 | The Regents Of The University Of California | Dajanje rastnih faktorjev za zdravljenje motenj CŽS |
| TWI445544B (zh) | 2007-05-01 | 2014-07-21 | Biogen Idec Inc | 增進血管形成之組合物及方法 |
-
2005
- 2005-08-18 DK DK05789285.3T patent/DK1786454T3/da active
- 2005-08-18 AU AU2005277226A patent/AU2005277226B2/en not_active Ceased
- 2005-08-18 JP JP2007528061A patent/JP4852545B2/ja not_active Expired - Fee Related
- 2005-08-18 EP EP05789285A patent/EP1786454B1/en not_active Expired - Lifetime
- 2005-08-18 BR BRPI0514534-1A patent/BRPI0514534A/pt not_active IP Right Cessation
- 2005-08-18 SI SI200531099T patent/SI1786454T1/sl unknown
- 2005-08-18 UA UAA200702764A patent/UA92590C2/uk unknown
- 2005-08-18 KR KR1020077005926A patent/KR101215697B1/ko not_active Expired - Fee Related
- 2005-08-18 EA EA200700460A patent/EA013565B1/ru not_active IP Right Cessation
- 2005-08-18 WO PCT/US2005/029637 patent/WO2006023781A2/en not_active Ceased
- 2005-08-18 EP EP10170146.4A patent/EP2238983B1/en not_active Expired - Lifetime
- 2005-08-18 CN CN2012104009059A patent/CN102924585A/zh active Pending
- 2005-08-18 NZ NZ553431A patent/NZ553431A/en not_active IP Right Cessation
- 2005-08-18 KR KR1020117022960A patent/KR20110126732A/ko not_active Ceased
- 2005-08-18 CA CA2577755A patent/CA2577755C/en not_active Expired - Fee Related
- 2005-08-18 DE DE602005022457T patent/DE602005022457D1/de not_active Expired - Lifetime
- 2005-08-18 GE GEAP20059928A patent/GEP20115196B/en unknown
- 2005-08-18 AT AT05789285T patent/ATE474586T1/de active
- 2005-08-18 US US11/573,773 patent/US8263553B2/en not_active Expired - Fee Related
- 2005-08-18 PL PL05789285T patent/PL1786454T3/pl unknown
- 2005-08-18 MX MX2007002029A patent/MX2007002029A/es active IP Right Grant
- 2005-08-18 RS RSP-2010/0386A patent/RS51453B/sr unknown
- 2005-08-18 PT PT05789285T patent/PT1786454E/pt unknown
- 2005-08-18 HR HR20100474T patent/HRP20100474T1/hr unknown
- 2005-08-18 EP EP10181609A patent/EP2335713A3/en not_active Withdrawn
-
2007
- 2007-02-13 IL IL181311A patent/IL181311A/en not_active IP Right Cessation
- 2007-02-16 ZA ZA2007/01395A patent/ZA200701395B/en unknown
- 2007-03-19 NO NO20071449A patent/NO20071449L/no not_active Application Discontinuation
-
2010
- 2010-04-19 IL IL205201A patent/IL205201A0/en unknown
- 2010-10-20 CY CY20101100936T patent/CY1111136T1/el unknown
-
2011
- 2011-05-13 JP JP2011108760A patent/JP2011155987A/ja not_active Withdrawn
-
2012
- 2012-07-03 US US13/541,302 patent/US20130096065A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510518A5 (enExample) | ||
| WO2008022759A3 (en) | Specific and high affinity binding proteins comprising modified sh3 domains of fyn kinase | |
| JP2013515055A5 (enExample) | ||
| NZ627111A (en) | Variants of activin iib receptor polypeptides and uses thereof | |
| JP2018510622A5 (enExample) | ||
| JP2013515057A5 (enExample) | ||
| IL308851B2 (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| HRP20200503T1 (hr) | Fuzijski proteini | |
| NZ590050A (en) | Fgf21 mutants and uses thereof | |
| JP2020500015A5 (enExample) | ||
| NZ630484A (en) | Compositions and methods for treatment of metabolic disorders and diseases | |
| JP2010534060A5 (enExample) | ||
| JP2014506135A5 (enExample) | ||
| JP2014508510A5 (enExample) | ||
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| HRP20240135T1 (hr) | Fgf21 mutanti i njihove upotrebe | |
| MX348154B (es) | Anticuerpos de enlace a il-1-beta y fragmentos de los mismos. | |
| HRP20231496T1 (hr) | Cistein proteaza | |
| EP2476698A3 (en) | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides | |
| JP2010529860A5 (enExample) | ||
| WO2010013012A3 (en) | Hypothermia inducing polypeptides and uses thereof | |
| JP2018538356A5 (enExample) | ||
| JP2019530441A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JP2018535972A5 (enExample) |